Table 1 Characteristics of patients according to their vital status.
From: Obesity and mortality in critically ill COVID-19 patients with respiratory failure
Overall | Survivors | Non-survivors | p-value | |
|---|---|---|---|---|
(n = 222) | (n = 177) | (n = 45) | ||
Age at admission | 64.0 (55.3–72.0) | 62.0 (54.0–70.0) | 72 (62.0–75.0) | <0.001 |
18–45 years | 19 (8.6) | 19 (10.8) | 0 (0.0) | 0.007 |
45–54 years | 34 (15.5) | 28 (15.9) | 6 (13.6) | |
5–64 years | 63 (28.6) | 53 (30.1) | 10 (22.7) | |
65–74 years | 72 (32.7) | 57 (32.4) | 15 (34.1) | |
75 years and more | 32 (14.5) | 19 (10.8) | 13 (29.5) | |
Male sex | 160 (72.1) | 128 (72.3) | 32 (71.1) | 1.000 |
BMI (kg/m2) | 29.1 (25.8–32.8) | 29.3 (25.9–32.8) | 28.7 (25.7–32.3) | 0.251 |
BMI categories | 0.024 | |||
Normal weight | 34 (15.3) | 28 (15.8) | 6 (13.3) | |
Overweight | 92 (41.4) | 72 (40.7) | 20 (44.4) | |
Moderate obesity | 80 (36.1) | 69 (39.0) | 11 (24.4) | |
Severe obesity | 16 (7.2) | 8 (4.5) | 8 (17.9) | |
Diabetes mellitus | 59 (26.6) | 44 (24.9) | 15 (33.3) | 0.337 |
Hypertension | 108 (48.6) | 78 (44.1) | 30 (66.7) | 0.011 |
Dyslipidemia | 79 (35.6) | 56 (31.6) | 23 (51.1) | 0.024 |
Chronic pulmonary disease | 42 (18.9) | 29 (16.4) | 13 (28.9) | 0.089 |
Including COPD | 14 (6.3) | 5 (2.8) | 9 (20.0) | <0.001 |
Including OSAS | 22 (9.9) | 16 (9.0) | 6 (13.3) | 0.561 |
Cardiovascular disease | 54 (24.3) | 39 (22.0) | 15 (33.3) | 0.167 |
Including CHD | 31 (14.0) | 20 (11.3) | 11 (24.4) | 0.042 |
including chronic heart failure | 5 (2.3) | 3 (1.7) | 2 (4.5) | 0.568 |
Immunodeficiency | 24 (10.8) | 17 (9.6) | 7 (15.6) | 0.379 |
Including immunosuppressant medication | 9 (4.1) | 7 (4.0) | 2 (4.4) | 1.000 |
Including active cancer | 9 (4.1) | 5 (2.8) | 4 (8.9) | 0.156 |
Chronic kidney disease | 15 (6.8) | 8 (4.5) | 7 (15.6) | 0.021 |
Neurological disorder | 10 (4.5) | 7 (4.0) | 3 (6.7) | 0.703 |
Number of comorbidities | <0.001 | |||
0 | 71 (32.0) | 66 (37.3) | 5 (11.1) | |
1 | 56 (25.2) | 47 (26.6) | 9 (20.0) | |
2 | 47 (21.2) | 33 (18.6) | 14 (31.1) | |
3 and more | 48 (21.6) | 31 (17.5) | 17 (37.8) | |
ARDS severitya | <0.001 | |||
Mild | 13 (5.9) | 13 (7.3) | 0 (0) | |
Moderate | 109 (49.1) | 98 (55.4) | 11 (24.4) | |
Severe | 100 (45) | 66 (37.3) | 34 (75.6) | |
PaO2/FiO2 (mmHg) | 109 (79.0–142.0) | 118.5 (84.0–153.0) | 85 (70.0–97.0) | <0.001 |
Mechanical ventilation | 183 (82.4) | 141 (79.7) | 42 (93.3) | 0.053 |
Mechanical ventilation duration (days) | 12.5 (8.0-18.0) | 12.0 (7.0-18.0) | 13.0 (8.0-19.0) | 0.518 |
Hydroxychloroquine | 31 (14.3) | 25 (14.5) | 6 (13.3) | 1.000 |
Antiviral therapy | 42 (19.0) | 32 (18.2) | 10 (22.2) | 0.686 |
Corticosteroids | 53 (23.9) | 35 (19.8) | 18 (40.0) | 0.008 |
SAPS II | 44.5 (32.3–62.0) | 42.0 (28.0–59.0) | 62.0 (44.0–75.0) | <0.001 |
SOFA score | 7.0 (4.0–8.0) | 7.0 (4.0–8.0) | 8.0(7.0–11.0) | <0.001 |
ICU length of stay (days) | 13.0 (5.0–22.0) | 13.0 (5.0–22.0) | 12.0 (6.0–19.0) | 0.360 |
Length of hospital stay (days) | 18.0 (10.0–28.0) | 20.0 (12.0–29.0) | 13.0 (7.0–22.0) | 0.001 |
